Valley Fever Solutions

Valley Fever Solutions, Inc. (VFS) is an Arizona-based corporation dedicated to developing Nikkomycin Z (NikZ) as a highly effective therapy for Valley Fever (VF), a debilitating orphan disease. With over 60,000 people affected annually, VF causes significant pain and suffering, leading to thousands of hospitalizations and deaths. VFS aims to provide a dramatically superior treatment option for VF patients, offering hope for reducing relapse rates and improving overall outcomes.

NikZ, a first-in-class antifungal medication, has shown promising results in pre-clinical studies, demonstrating its ability to suppress fungal growth and eliminate detectable Valley Fever residual fungus. VFS is preparing for Phase IIa trials in sick humans, with the goal of collecting approvable data within 18 months. With its potential to revolutionize VF therapy and address the unmet needs of patients who cannot tolerate current treatments, VFS seeks to make a significant impact in the field of fungal infections.

Generated from the website